Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cellectar Biosciences

Explore full profile

A pharmaceutical research company specializing in cancer drugs

Madison, United StatesFounded 2002Biotech & Life Sciences
Total funding $10–50M Disclosed equity funding

About Cellectar Biosciences

Cellectar Biosciences, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of drugs for cancer treatment. The company leverages its proprietary phospholipid drug delivery platform to create phospholipid drug conjugates (PDCs) that specifically target cancer cells. This targeted approach aims to improve the efficacy of cancer treatments while minimizing off-target effects, thereby enhancing patient safety.

Read full description

Cellectar operates in the biopharmaceutical sector, focusing on oncology. Its clients primarily include healthcare providers, research institutions, and potentially patients undergoing cancer treatment. The company's business model revolves around the development and commercialization of its proprietary PDCs. Revenue is generated through the sale of these drugs, partnerships, and potentially licensing agreements.

The market for Cellectar's products is highly specialized, targeting various forms of cancer. The company's innovative approach and proprietary technology position it as a significant player in the oncology drug development space.

Source: Dealroom company data

At a glance

Founded
2002
Headquarters
Madison, United States
Listing
IPO 2005
Sector
Biotech & Life Sciences

Latest news

Press, funding announcements and product moves mentioning Cellectar Biosciences.

See all news

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Cancer Institute (NCI)

Series A1 investor entered at this stage

  • Venture Investors Health Fund

Series B and later9 investors entered at this stage

  • Nantahala Capital Management
  • Second Line
  • Janus Henderson Investors
  • Caligan Partners
  • Balyasny Asset Management
  • Stonepine Capital Management
  • SilverArc Capital
  • StemPoint Capital
  • Empery Asset Management
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Madison HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cellectar Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cellectar Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.